(B) Observed rate of structural joint damage non-progression at Weeks 96 and 216 | ||
Observed case | Week 0 CZP dose combined (n=273) | |
Time point | Week 96 | Week 216 |
Assessed for progression, n | 214 | 186 |
Rate of non-progression (CFB in mTSS ≤0.5), n (%)* | 180 (84.1) | 145 (78.0) |
Rate of non-progression (CFB in mTSS ≤0), n (%)* | 157 (73.4) | 121 (65.1) |
Data are shown for the Randomised Set.
*Percentage is based on the number of participants assessed for progression at the visit.
CFB, change from baseline; CZP, certolizumab pegol; LS, least squares; MMRM, mixed-effect model for repeated measures; mTSS, modified Total Sharp Score.